The
following potential common share equivalents were excluded from the calculation of diluted net income per share because their effect
would have been anti-dilutive in the period presented (in thousands):
Schedule
of Antidilutive Securities Earnings Per Share
| | |
2025 | | |
2024 | |
| | |
Nine Months Ended
September 30, | |
| | |
2025 | | |
2024 | |
| Convertible preferred stock | |
| 31,206 | | |
| 25,247 | |
| Common Stock Warrants | |
| 1,421 | | |
| - | |
| Preferred Stock Warrants | |
| 247 | | |
| 247 | |
| Stock options | |
| 7,050 | | |
| 5,027 | |
| Total potential common stock excluded from net loss per share | |
| 39,924 | | |
| 30,521 | |
|
The
following potential common share equivalents were excluded from the calculation of diluted net income per share in FY 2024 because their
effect would have been anti-dilutive in the period presented (in thousands):
Schedule
of Antidilutive Securities Earnings Per Share
| | |
2024 | | |
2023 | |
| | |
Years
Ended December
31, | |
| | |
2024 | | |
2023 | |
| Convertible
preferred stock | |
| 26,560 | | |
| 22,460 | |
| Stock
options | |
| 5,027 | | |
| 178 | |
| Total
potential common stock excluded from net loss per share | |
| 31,587 | | |
| 22,638 | |
|